ArticleBreast cancer research and treatment2025
Arsenic in drinking water and breast cancer: a case-control study from a high exposure area in Northern Chile.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human papillomavirus (HPV) genotypes extended prevalence in the female population from a city in Northern Chile.BMC women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeExposure to arsenic in drinking water is a cause of lung, bladder, and skin cancer, however the relation between arsenic and breast cancer is unclear. Northern Chile had high levels of arsenic in drinking water (up to 900 µg/l) between 1950 and 1970, facilitating the study of outcomes with long latency. We conducted a breast cancer case-control study in Northern Chile (2014-2018) and analyzed 505 incident breast cancer cases and 409 population-based female controls with data collected on lifetime exposure to arsenic and potential confounders.
methodsWe identified cases in collaboration with cancer committees, hospitals, and medical facilities in the study area. Controls were recruited from the Chile Voter Registry. Logistic regression was used to assess the relationship between arsenic exposure and breast cancer adjusting for education and age. We evaluated cumulative, lifetime average and highest single year exposure with tertiles and quartiles and population weighted controls based on age and region of residence.
resultsExposure levels were high in both cases and controls, with median (interquartile range) values of: 52 (15-84) and 42 (10-106) μg/L for average lifetime concentration, respectively. Adjusted odds ratios (OR) for tertile of cumulative exposure to arsenic concentrations in water (< 1.17, 1.17-5.16, and ≥ 5.17 mg) were 1.00, 0.85 [95% confidence interval (CI), 0.60-1.18], and 1.10 (0.79-1.55). Results were similar for lifetime average and single-highest year exposure metrics.
conclusionWe did not find evidence of increased odds of higher arsenic exposure among incident breast cancer cases compared to female population controls.
Indexed as
Identifiers
40629209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.